A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY).
Kota Kawabata, Koichi Yasuda, Satoaki Nakamura et al.
✦ AI-curated · Sources linked
In 30 seconds
JCOG2405 (ELDER-WEEKLY) is a planned multicenter, randomized phase III trial comparing radiotherapy plus weekly cisplatin (40 mg/m2) with radiotherapy alone in patients aged ≥70 years with locally advanced head and neck squamous cell carcinoma who are unfit for high-dose cisplatin. The trial is designed to test whether weekly cisplatin chemoradiotherapy improves overall survival, its primary endpoint. The abstract reports the study design and planned enrollment, but no efficacy or safety results.
Key findings
- The trial will enroll 250 patients aged ≥70 years across 59 institutions over 5 years.
- The primary endpoint is overall survival; the study is designed to test superiority of weekly cisplatin chemoradiotherapy over radiotherapy alone.
Why it matters
High-dose cisplatin may be intolerable for some older patients, while the optimal treatment for those unable to receive it remains unclear. This trial addresses that evidence gap by directly comparing weekly cisplatin chemoradiotherapy with radiotherapy alone in this population. Its results may clarify whether adding weekly cisplatin improves survival, but the abstract provides no outcome data yet.
What to keep in mind
This is a trial design report; efficacy and safety outcomes are not yet reported in the abstract.